<DOC>
	<DOCNO>NCT01003418</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity two dos H1N1 candidate vaccine administer child age 8 12 week time first vaccination .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity GSK Biologicals ' Pandemic Influenza ( H1N1 ) Candidate Vaccine Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LARs ) comply requirement protocol Children , male female , age 8 12 week time first study vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy child , establish medical history clinical examination enter study . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Born gestation period &gt; = 36 &lt; = 42 week . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine plan use study period . Acute disease time enrolment . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . History neurological disorder seizure . A family history congenital hereditary immunodeficiency . Receipt systemic glucocorticoid within one month study enrolment , cytotoxic immunosuppressive drug since birth . Administration vaccine within two week study enrolment . Administration immunoglobulins and/or blood product since birth plan administration study . Previous administration H1N1 vaccine , seasonal influenza vaccine . Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis , Haemophilus influenzae type b , and/or Streptococcus pneumoniae exception vaccine first dose give within first two week life accord national recommendation . History intercurrent diphtheria , tetanus , pertussis , poliomyelitis , Haemophilus influenzae type b disease . Major congenital defect serious chronic illness . Child care . Any known suspected allergy constituent influenza , DTPaIPV/Hib pneumococcal study vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza , DTPaIPV/Hib pneumococcal vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK2340272A</keyword>
	<keyword>H1N1 pandemic influenza</keyword>
</DOC>